Atlas Trials

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Clinical trial NCT05247905 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05247905
Sponsor
Alliance for Clinical Trials in Oncology
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Pancreatic Neuroendocrine TumorUnresectable Pancreatic Neuroendocrine Carcinoma
Start date
2023-02-16
Primary completion
2028-03-31
Enrollment
31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.